1049026-49-4

Usage

Uses

Used in Flavor and Fragrance Industry:
2-BROMO-5-(METHYLTHIO)PYRAZINE is used as a flavor and fragrance additive for its distinct earthy and meaty aroma, enhancing the sensory experience in food and beverage products. Its high stability and resistance to oxidation contribute to its long-lasting aromatic properties, making it a popular choice in the industry.
Used in Pharmaceutical Production:
2-BROMO-5-(METHYLTHIO)PYRAZINE serves as a valuable synthetic intermediate in the production of various pharmaceuticals, playing a crucial role in the development of new drugs and medicinal compounds.
Used in Organic Chemistry:
As a pyrazine derivative, 2-BROMO-5-(METHYLTHIO)PYRAZINE is utilized in organic chemistry for the synthesis of complex organic molecules, contributing to advancements in chemical research and the creation of novel chemical entities.

InChI:InChI=1S/C5H5BrN2S/c1-9-5-3-7-4(6)2-8-5/h2-3H,1H3

Upstream product

• 23229-26-7 2-5-dibromopyrazine 
• 5188-07-8 sodium thiomethoxide 

Downstream Products

• 1177421-54-3 2-bromo-5-(methylsulfonyl)pyrazine 

Relevant academic research and scientific papers

NOVEL COMPOUNDS AS GPR119 AGONISTS

The present invention relates to novel compounds of formula (I) as GPR119 agonist, composition compositions containing such compounds and method of preparation thereof.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

NOVEL PHENYLPYRROLE DERIVATIVE

The present invention relates to a compound or a pharmacologically acceptable salt thereof having superior glucokinase activating activity, and is a compound represented by general formula (I), or pharmacologically acceptable salt thereof: [wherein, A represents, for example, an oxygen atom or sulfur atom, R1 represents, for example, a C1-C6 alkyl group, a C1-C6 alkoxy group or a C1-C6 halogenated alkyl group, A and R1 together with the carbon atom bonded thereto form a heterocyclic group that may be substituted with 1 to 3 group(s) independently selected from Substituent Group α, R2 represents a phenyl group that may be substituted with 1 to 5 group(s) independently selected from Substituent Group α or a heterocyclic group that may be substituted with 1 to 3 group(s) independently selected from Substituent Group α, R3 represents a hydroxy group or a C1-C6 alkoxy group, and Substituent Group α consists of, for example, a halogen atom, a C1-C6 alkyl group, a C1-C6 alkyl group substituted with 1 or 2 hydroxy group(s), a C1-C6 alkylsulfonyl group, and a group represented by the formula -V-NR5R6 (wherein, V represents a carbonyl group or a sulfonyl group, and R5 and R6 may be the same or different and respectively represent a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 together with the nitrogen atom bonded thereto form a 4- to 6-membered saturated heterocycle that may be substituted with 1 or 2 group(s) independently selected from a C1-C6 alkyl group and a hydroxy group, and the 4- to 6-membered saturated heterocycle may further contain one oxygen atom or nitrogen atom)].